-
×
Kisspeptin-10 10mg & 5mg (Kp-10) (10mg Vial)
1 × $85.00
Subtotal: $85.00
PT-141
$35.00
A cyclic heptapeptide melanocortin-receptor agonist (an α-MSH analog), supplied as sterile lyophilized powder for in-vitro melanocortin-pathway research.
Tested by Freedom Diagnostics TestingHPLC purity + LC-MS identityLot-matched COA on-site
For research use only. This product is a laboratory research chemical. It is not for human or veterinary use, not a drug, supplement, or food, and not intended to diagnose, treat, cure, or prevent any disease. Sold only to qualified researchers and institutions.
What is PT-141?
PT-141, also known as bremelanotide, is a cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH) that acts as an agonist at melanocortin receptors, principally the MC4R subtype with additional MC1R activity. Its cyclic structure confers receptor selectivity and metabolic stability relative to the linear α-MSH scaffold from which it is derived, and it engages Gs / adenylyl-cyclase / cAMP signaling in receptor-expressing cells. In the laboratory it is widely used as a reference MC4R agonist tool compound.
Research areas where laboratories buy PT-141 for in vitro work include MC4R and MC1R receptor-binding and cAMP-accumulation assays, central melanocortin-system signaling studies in cell and rodent models, receptor-subtype selectivity profiling across MC1R–MC5R, structure-activity studies of cyclic α-MSH analogs, and comparative pharmacology against linear melanocortin peptides.
Every lot, independently verified
Independently third-party tested and matched to the lot ID printed on your vial. Values below are from the latest released lot.
≥99%
HPLC-UV Purity
Passed full QC panel
independent third-party lab (Freedom Diagnostics Testing) accredited lab
Per-lot HPLC-UV + LC-MS · independent ISO 17025 lab
Lot details
ProductPT-141 10 mg
LotPer-batch on COA
AppearanceWhite lyophilized powder
ReleaseFull QC panel per lot
DocumentationLot-matched COA
Full QC panel · ISO 170256 assays
Purity (HPLC-UV)≥99% per lot ✓
Identity (LC-MS)Bremelanotide ✓
HPLC conformity (2×)Confirmed ✓
Heavy metals (ICP-MS)Not Detected ✓
SterilityNo Growth ✓
Endotoxin (USP <85>)Within limits ✓
Every lot is released against Koi’s full QC panel — HPLC purity, LC-MS identity, heavy metals, sterility, and endotoxin — by an independent ISO/IEC 17025-accredited laboratory. The lot-specific certificate is published in our public COA library and matched to the lot ID printed on the vial.
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
Product Specifications
CompoundPT-141 / bremelanotide (cyclic melanocortin MC4R/MC1R agonist)
Vial size10 mg
Purity≥99% by HPLC
Identity confirmationMass spectrometry
FormWhite lyophilized powder
Appearance after reconstitutionClear, colorless solution
ManufacturingSynthesized and lyophilized in the United States
Quality testingIndependent independent third-party laboratory release
Molecular Profile
ClassMelanocortin MC4R/MC1R agonist
TypeCyclic heptapeptide (α-MSH analog)
Molecular formulaC50H68N14O10
Molecular weight1025.18 g/mol
CAS number189691-06-3
Other namesBremelanotide · PT-141
Structure classCyclic heptapeptide · α-MSH analog
Storage & Handling
AppearanceWhite lyophilized powder
SolubilitySterile water · neutral pH
Storage · powder−20 °C, desiccated, dark (−80 °C long-term)
In solution2–8 °C; aliquot & freeze, avoid freeze-thaw
PT-141 Mechanism of Action
- Acts as an agonist at melanocortin receptors, principally MC4R (with MC1R activity), in the central melanocortin system.
- Engages Gs / adenylyl-cyclase / cAMP signaling in receptor-expressing cell models.
- Derived from the α-MSH scaffold; the cyclic structure confers receptor selectivity and metabolic stability.
- Studied for melanocortin-mediated CNS signaling pathways in preclinical models.
- Distinct from peripheral melanocortin (pigmentation) pathways by receptor-subtype selectivity.
- Serves as the reference MC4R agonist tool compound for melanocortin pharmacology.
PT-141 Research Applications
- MC4R and MC1R receptor binding and cAMP-accumulation assays.
- Central melanocortin-system signaling studies in cell and rodent models.
- Receptor-subtype selectivity profiling across MC1R–MC5R.
- Structure-activity studies of cyclic α-MSH analogs.
- Behavioral neuroscience models of melanocortin signaling.
- Comparative pharmacology against linear melanocortin peptides.
Why Buy PT-141 from Koi Peptides?
- Every batch of Koi PT-141 is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
- Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and endotoxin assay for sterility readiness.
- The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
- Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
- Cone, R. D. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews, 27(7), 736–749. doi.org/10.1210/er.2006-0034
- Molinoff, P. B., et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. International Journal of Impotence Research, 15(Suppl 5), S38–S42.
- Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930. doi.org/10.1016/j.peptides.2005.01.029
- Yang, Y. (2011). Structure, function and regulation of the melanocortin receptors. European Journal of Pharmacology, 660(1), 125–130. doi.org/10.1016/j.ejphar.2010.12.020
Regulatory Status
FDA, WADA anti-doping, and compounding status — provided for research context.FDA StatusBremelanotide is FDA-approved as Vyleesi (approved June 2019) for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and is available as a prescription drug product for human therapeutic use under prescriber oversight. The research-grade PT-141 supplied by Koi Peptides is synthesized independently for in vitro laboratory research only — it is not the approved Vyleesi drug product, not formulated, packaged, or labeled for human use, not equivalent to or a substitute for the approved drug, and not authorized for any human or veterinary use.
WADA Anti-Doping StatusPT-141 (bremelanotide) is not currently named on the WADA Prohibited List. As with all compounds, athletes and researchers should consult the current WADA List directly, since classifications are reviewed annually. This information is provided for research context only and does not constitute compliance advice.
Compounding Pharmacy StatusKoi Peptides is a chemical research supplier — not a compounding pharmacy or outsourcing facility under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act — and supplies no compounded preparations of any kind. The research-grade material supplied here is not pharmaceutical-grade material for sterile compounding for human use.
DisclaimerFor research use only. Not for human or veterinary use. PT-141 is supplied to qualified research professionals for in vitro laboratory study. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act. By purchasing, the buyer agrees this material will not be introduced into humans or animals. Misuse may violate federal, state, or local laws.
Be the first to review “PT-141”
Related products
Reviews
There are no reviews yet.